LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bioperfectus SARS-CoV-2 Antigen Rapid Test Kit with High Sensitivity and Specificity Assists in Fight against COVID-19 Pandemic

By LabMedica International staff writers
Posted on 12 Mar 2021
Print article
Image: Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit (Photo courtesy of Jiangsu Bioperfectus Technologies Co., Ltd.)
Image: Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit (Photo courtesy of Jiangsu Bioperfectus Technologies Co., Ltd.)
Jiangsu Bioperfectus Technologies Co., Ltd.’s (Shanghai, China) Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with clinically proven high sensitivity and specificity is playing an important role in COVID-19 diagnostics as a fast and cost-efficient antigen test.

While the reverse transcription real-time polymerase chain reaction (RT-PCR) assay, which is a nucleic acid amplification test (NAAT), remains the “gold standard” for COVID-19 diagnosis, rapid antigen tests, which detect the presence of viral proteins (antigens) are proving to be a faster and cheaper way for communities to detect ongoing infection. Despite their growing demand, there has been a shortage of COVID-19 rapid antigen tests in Europe due to the heavy reliance of EU countries on rapid antigen tests as a surplus testing option through the next phase of the pandemic, slow pace of vaccination, and a comparatively weak supply chain.

Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with its clinical proven accuracy is helping healthcare workers to quickly find out whether someone is currently at risk of spreading the disease, which will effectively curb the further spread of the virus. Bioperfectus COVID-19 rapid antigen test has been clinically proven to have high sensitivity of 96.7% and specificity of 97.9% by several institutes worldwide. Additionally, in a recent evaluation performed by the UK Department of Health and Social Care, Bioperfectus COVID-19 rapid antigen test showed no drop off in sensitivity when compared with the wild type with respect to the following variants - VOC1 Kent, UK, B.1.1.7 and VOC2 South Africa, B.1.351.

Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test offers nasal, nasopharyngeal and oropharyngeal swab in both sterile tube and sterile peel-down pouch packages to meet the varied testing demands in different clinical laboratories across the world. Bioperfectus COVID-19 rapid antigen test also offers additional advantages such as fast results within 15 minutes, easy three-step use, swab with optional protective jacket to avoid biohazard, quality control for reliable results, and inclusion of all necessary components in the kit.

Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.